Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 53310-53311 [2015-21897]
Download as PDF
<![CDATA[
53310
Federal Register / Vol. 80, No. 171 / Thursday, September 3, 2015 / Notices
FEDERAL MARITIME COMMISSION
Agency Information Collection
Activites; New Information Collection
Request
Federal Maritime Commission.
Notice and request for
comments.
AGENCY:
ACTION:
As part of its continuing effort
to reduce paperwork and respondent
burden, and as required by the
Paperwork Reduction Act of 1995
(PRA), 44 U.S.C. 3501 et seq., the
Federal Maritime Commission (FMC or
Commission) announces plans to submit
a Generic Information Collection
Request (ICR) to the Office of
Management and Budget (OMB) to
collect information for requests for
dispute resolution services submitted to
its Office of Consumer Affairs and
Dispute Resolution Services (CADRS).
Prior to submitting the ICR to OMB, the
FMC invites comments from the public
on the ICR.
DATES: Comments must be received by
November 3, 2015.
ADDRESSES: Submit your comments to
omd@fmc.gov (as attachments
preferably in Microsoft Word or PDF), or
mail comments to: Vern W. Hill,
Managing Director, Office of the
Managing Director, Federal Maritime
Commission, 800 North Capitol Street
NW., Washington, DC 20573–0001.
FOR FURTHER INFORMATION CONTACT: To
request more information or to obtain a
copy of the data collection plans and
draft instruments, email omd@fmc.gov
or call Donna Lee at (202) 523–5800.
When submitting comments or
requesting information, please include
the information collection request title
for reference. Comments submitted in
response to this Notice will be included
or summarized in the ICR to OMB. All
comments are part of the public record
and subject to disclosure.
SUPPLEMENTARY INFORMATION:
Title: Request for Dispute Resolution
Service.
OMB Control Number: New.
Type of Review: New Generic
Information Collection.
Frequency of Response: On occasion.
Respondents/Affected Public:
Companies or individuals seeking
ombuds or mediation assistance from
the Federal Maritime Commission’s
Office of Consumer Affairs and Dispute
Resolution Services.
Estimated Total Number of Potential
Annual Responses: 1,000.
Estimated Total Number of Responses
for each Respondent: 1.
Estimated Total Annual Burden
Hours per Response: 20 minutes.
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:42 Sep 02, 2015
Jkt 235001
Total Estimated Number of Annual
Burden Hours: 333.
Abstract: As requested by the
shipping public and the regulated
industry, the FMC, through CADRS,
provides ombuds and mediation
services to assist parties in resolving
international ocean cargo shipping or
passenger vessel (cruise) disputes
without resorting to litigation or
administrative adjudication. These
functions focus on addressing issues
that members of the regulated industry
and the shipping public may encounter
at any stage of a commercial or customer
dispute. In order to provide its ombuds
and mediation services, CADRS needs
certain identifying information about
the involved parties, shipments, and
nature of the dispute. In response to
requests for assistance from the public,
CADRS requests this information from
parties seeking its assistance. The
collection and use of this information
on a cargo or cruise dispute is integral
to CADRS staff’s ability to efficiently
review the matter and provide
assistance. Aggregated information may
be used for statistical purposes.
Currently, this information is collected
in a non-uniform manner in response to
requests for CADRS assistance. https://
www.fmc.gov/resources/requesting_
cadrs_assistance.aspx.
As required by the Administrative
Dispute Resolution Act (ADRA), 5
U.S.C. 571–574, the information
contained in these forms is treated as
confidential and subject to the same
confidentiality provisions as
administrative dispute resolutions
pursuant to 5 U.S.C. 574. Except as
specifically set forth in 5 U.S.C. 574,
neither CADRS staff nor the parties to a
dispute resolution shall disclose any
informal dispute resolution
communication.
This information collection is subject
to the PRA. The FMC may not conduct
or sponsor a collection of information,
and the public is not required to
respond to an information collection,
unless it is approved by the OMB under
the PRA and displays a currently valid
OMB Control Number. In addition,
notwithstanding any other provisions of
law, no person shall be subject to
penalty for failing to comply with a
collection of information that does not
display a valid Control Number. See 5
CFR 1320.5(a) and 1320.6.
Request for Comments
The FMC solicits written comments
from all interested persons about the
proposed collection of information. The
Commission specifically solicits
information relevant to the following
topics: (1) Whether the collection of
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
information described above is
necessary for the proper performance of
the Commission’s functions, including
whether the information would have
practical utility; (2) whether the
estimated burden of the proposed
collection of information is accurate; (3)
whether the quality, utility, and clarity
of the information to be collected could
be enhanced; and (4) whether the
burden imposed by the collection of
information could be minimized by use
of automated, electronic, or other forms
of information technology.
The FMC will consider the comments
received and amend the ICR as
appropriate. The final ICR package will
then be submitted to OMB for review
and approval pursuant to 5 CFR
1320.10. FMC will issue another
Federal Register announcement
pursuant to 5 CFR 1320.5(a)(1)(iv) to
announce the submission of the ICR to
OMB and the opportunity to submit
additional comments to OMB. If you
have questions about this ICR or the
approval process, please contact the
person listed under FOR FURTHER
INFORMATION CONTACT.
Authority: 46 U.S.C. 40101 et seq.
Karen V. Gregory,
Secretary.
[FR Doc. 2015–21916 Filed 9–2–15; 8:45 am]
BILLING CODE 6731–AA–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
E:\FR\FM\03SEN1.SGM
03SEN1
Federal Register / Vol. 80, No. 171 / Thursday, September 3, 2015 / Notices
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than September 28,
2015.
A. Federal Reserve Bank of Dallas
(Robert L. Triplett III, Senior Vice
President) 2200 North Pearl Street,
Dallas, Texas 75201–2272:
1. Independent Bank Group, Inc.,
McKinney, Texas; to acquire 100
percent of the voting shares of Grand
Bank, Dallas, Texas.
Board of Governors of the Federal Reserve
System, August 31, 2015.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2015–21897 Filed 9–2–15; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3043]
Compressed Medical Gases-Warning
Letters for Specific Violations
Covering Liquid and Gaseous Oxygen;
Withdrawal of Compliance Policy
Guide
AGENCY:
Food and Drug Administration,
Liquid and Gaseous Oxygen’’ (CPG
7132a.16). Subsequently, the Agency’s
Manual of Compliance Policy Guides
was reorganized and this material
became Section 435.100. The CPG
provided guidance to FDA district
offices for issuing warning letters to
firms that are engaged in filling
cylinders with gas(es) for medical use
that are not operating in conformance
with the adulteration, misbranding,
and/or new drug provisions of the
Federal Food, Drug, and Cosmetic Act.
On March 15, 2015, FDA
implemented the revised Compliance
Program Guidance Manual (CPGM)
7356.002E, entitled ‘‘Compressed
Medical Gases,’’ available at https://
www.fda.gov/downloads/ICECI/
ComplianceManuals/
ComplianceProgramManual/
UCM125417.pdf. CPGM 7356.002E
instructs FDA staff regarding a range of
subjects, including, but not limited to,
the inspections and investigations,
regulatory and/or administrative action,
and the issuance of warning letters
related to compressed medical gases. As
the CPGM 7356.002E articulates FDA’s
current thinking on issuing warning
letters related to compressed medical
gases, CPG Section 435.100 is
withdrawn.
Dated: August 28, 2015.
Steven Solomon,
Deputy Associate Commissioner for
Regulatory Affairs.
[FR Doc. 2015–21874 Filed 9–2–15; 8:45 am]
BILLING CODE 4164–01–P
HHS.
ACTION:
Notice; withdrawal.
The Food and Drug
Administration (FDA) is announcing the
withdrawal of Compliance Policy Guide
(CPG) Section 435.100, entitled
‘‘Compressed Medical Gases—Warning
Letters for Specific Violations Covering
Liquid and Gaseous Oxygen.’’
DATES: The withdrawal is effective
September 3, 2015.
FOR FURTHER INFORMATION CONTACT:
Mary E. Kennelly, Office of Regulatory
Affairs, 10903 New Hampshire Ave.,
Bldg. 32, Rm. 4338, Silver Spring, MD
20993, 240–402–9577.
SUPPLEMENTARY INFORMATION: A
Compliance Policy Guide (CPG) on
medical gases was originally issued on
November 5, 1987, in the Agency’s
Manual of Compliance Policy Guides. In
a notice published in the Federal
Register of September 16, 1992 (57 FR
42757), FDA announced the availability
of a revised CPG on this topic entitled
‘‘Compressed Medical Gases—Warning
Letters for Specific Violations Covering
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:42 Sep 02, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3137]
Advisory Committee; Nonprescription
Drugs Advisory Committee, Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of advisory
committee.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
renewal of the Nonprescription Drugs
Advisory Committee by the
Commissioner of Food and Drugs (the
Commissioner). The Commissioner has
determined that it is in the public
interest to renew the Nonprescription
Drugs Advisory Committee for an
additional 2 years beyond the charter
expiration date. The new charter will be
in effect until the August 27, 2015,
expiration date.
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
53311
Authority for the
Nonprescription Drugs Advisory
Committee will expire on August 27,
2017, unless the Commissioner formally
determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT:
Moon Hee V. Choi, Division of Advisory
Committee and Consultant
Management, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001,
NDAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services pursuant to 45 CFR part 11 and
by the General Services Administration,
FDA is announcing the renewal of the
Nonprescription Drugs Advisory
Committee. The Committee is a
discretionary Federal advisory
committee established to provide advice
to the Commissioner. The Committee
advises the Commissioner or designee
in discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
available data concerning the safety and
effectiveness of over-the-counter
(nonprescription) human drug products,
or any other FDA-regulated product, for
use in the treatment of a broad spectrum
of human symptoms and diseases and
advises the Commissioner either on the
promulgation of monographs
establishing conditions under which
these drugs are generally recognized as
safe, effective, not misbranded, and on
the approval of new drug applications.
The Committee serves as a forum for the
exchange of views regarding the
prescription and nonprescription status,
including switches from one status to
another. The Committee may also
conduct peer review of Agency
sponsored intramural and extramural
scientific biomedical programs in
support of FDA’s mission and regulatory
responsibilities.
The Committee shall consist of a core
of 10 voting members including the
Chair. Members and the Chair are
selected by the Commissioner or
designee from among authorities
knowledgeable in the fields of internal
medicine, family practice, clinical
toxicology, clinical pharmacology,
pharmacy, dentistry, and related
specialties. Members will be invited to
serve for overlapping terms of up to 4
years. Almost all non-Federal members
of this committee serve as Special
Government Employees. The core of
DATES:
E:\FR\FM\03SEN1.SGM
03SEN1
]]>Agencies
[Federal Register Volume 80, Number 171 (Thursday, September 3, 2015)]
[Notices]
[Pages 53310-53311]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-21897]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The applications will also be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the
[[Page 53311]]
nonbanking company complies with the standards in section 4 of the BHC
Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities
will be conducted throughout the United States.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than September 28, 2015.
A. Federal Reserve Bank of Dallas (Robert L. Triplett III, Senior
Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:
1. Independent Bank Group, Inc., McKinney, Texas; to acquire 100
percent of the voting shares of Grand Bank, Dallas, Texas.
Board of Governors of the Federal Reserve System, August 31,
2015.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2015-21897 Filed 9-2-15; 8:45 am]
BILLING CODE 6210-01-P
